Adam Utley, PhD, is our Founder and CEO. Adam completed his PhD in Tumor Immunology in the lab of Kelvin Lee, MD, Roswell Park Comprehensive Cancer Center. His insight into the development of immune cell-based therapies led him to found the company in 2016, even before the first cell-based therapy (Kymriah CAR-T cell therapy) was approved by the FDA in 2017. His scientific career has focused on B and T cell function, as well as how the dysregulation of immune cells leads to cancer progression. He has been invited to speak at both national and international conferences and his work has been published in several high tier journals (Blood, Nature Communications, Cell Reports, Journal of Immunology). He is a current member of the American Association of Immunologists and the American Society of Hematology.